FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

By V. Heinemann, L. V. von Weikersthal, T. Decker, A. Kiani, U. Vehling‐Kaiser, S. Al-Batran, T. Heintges, C. Lerchenmüller, C. Kahl, G. Seipelt and 17 more. The Lancet Oncology, 2014

1,640 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/053b8b59288ed25606da79897358cec3a4cc7232

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Cutsem
2. A. Cervantes
3. D. Arnold
4. B. Lueza
5. S. Tejpar
6. Fortunato Ciardiello
7. J. Douillard
8. A. Sobrero

Citations in the corpus

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “7 months) observed for patients with RAS wild-type tumours treated with cetuximab compared with those with KRAS exon 2 wild-type tumours treated with cetuximab [55].”
• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017, methodology): “Methods The present pooled analyses are based on data from the randomized CRYSTAL (NCT00154102) [33], PRIME (NCT00364013) [34], PEAK (NCT00819780) [35], FIRE-3 (NCT00433927) [36, 37], 1714 | Arnold et al. Volume 28 | Issue 8 | 2017 Downloaded from https://academic.oup.com/annonc/article-abstract/28/”
• Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (2017, methodology): “Study Design and Patients The CRYSTAL and FIRE-3 study designs, treatment parameters, andeligibilitycriteriahavebeenpreviously reported.(1-4)”